US Food and Drug Administration (USFDA) has granted emergency use authorization (EUA) to Kilpest India with its subsidiary -- 3B Blackbio Biotech India for its multiplex real-time PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19.
With this, 3B Blackbio Biotech India becomes first ever Indian molecular diagnostics company to receive US FDA-(EUA). Especially at times when more and more reliable testing is the need of the hour for India as well as other countries, TRUPCR will be reliable options for labs across the globe to perform the molecular testing for Covid-19 suspected individuals.
Kilpest India is one of India's leading agri-based companies. The Company manufactures, imports, exports, buys, and sells biological compounds derived from plants, animals, micro organisms.
